Journal of endodontics · 2025
Cetrimide-enhanced Calcium Hydroxide Paste: A Biocompatible and Bioactive Option for Regenerative Endodontics.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Iglesias Júlia Eick, Pinheiro Lucas Siqueira, Ferreira Gabriela Cardoso, Cuppini Marla, Collares Fabrício Mezzomo, Grecca Fabiana Soares
Аннотация
INTRODUCTION: This study compared the cytotoxicity, bioactivity, and biocompatibility of calcium hydroxide paste (CHP) with or without 0.2% cetrimide in microspheres (CETm) or in pure form (CET).
METHODS: CETm or CET were added to CHP and evaluated for cytocompatibility (3-(4,5-dimethyl-thiazoyl)-2,5-diphenyl-tetrazolium bromide assay) and bioactivity (Alizarin Red and alkaline phosphatase), using stem cells from the apical papilla. Biocompatibility was assessed by implanting polyethylene tubes containing the materials into rat subcutaneous tissue. One-way ANOVA followed by Tukey post hoc was used to analyze the results of 3-(4,5-dimethyl-thiazoyl)-2,5-diphenyl-tetrazolium bromide, alkaline phosphatase, and Alizarin Red assays. Kruskal-Wallis with Dunn's post hoc test was used for the biocompatibility test (P < .05).
RESULTS: All pastes exhibited cell viability above 100% and bioactivity in alkaline phosphatase and Alizarin Red assays. No abscesses, eosinophils, neutrophils, or giant cells were observed. After 90 days, all materials induced fibrous condensation, and inflammation decreased from mild to insignificant.
CONCLUSION: Adding CETm or CET to CHP may offer a potential intracanal medication for regenerative endodontic procedures, demonstrating favorable biological properties.
METHODS: CETm or CET were added to CHP and evaluated for cytocompatibility (3-(4,5-dimethyl-thiazoyl)-2,5-diphenyl-tetrazolium bromide assay) and bioactivity (Alizarin Red and alkaline phosphatase), using stem cells from the apical papilla. Biocompatibility was assessed by implanting polyethylene tubes containing the materials into rat subcutaneous tissue. One-way ANOVA followed by Tukey post hoc was used to analyze the results of 3-(4,5-dimethyl-thiazoyl)-2,5-diphenyl-tetrazolium bromide, alkaline phosphatase, and Alizarin Red assays. Kruskal-Wallis with Dunn's post hoc test was used for the biocompatibility test (P < .05).
RESULTS: All pastes exhibited cell viability above 100% and bioactivity in alkaline phosphatase and Alizarin Red assays. No abscesses, eosinophils, neutrophils, or giant cells were observed. After 90 days, all materials induced fibrous condensation, and inflammation decreased from mild to insignificant.
CONCLUSION: Adding CETm or CET to CHP may offer a potential intracanal medication for regenerative endodontic procedures, demonstrating favorable biological properties.